A company representative told CNBC that Cigna’s pharmacy benefits management unit will cap yearly spending growth for diabetes and weight loss medications at 15%. According to the spokeswoman, prescription expenditures are currently rising by 40% to 50% annually for some health plans.
The representative stated that Cigna’s Evernorth division reached deals with pharmaceutical companies Eli Lilly and Novo Nordisk as part of that endeavor. Cigna did not elaborate on the specifics of those agreements.
Given how common obesity is worldwide, an Eli Lilly representative stated on Thursday that companies have to “prioritize solutions that facilitate access to comprehensive and patient-centered” obesity therapy.
As part of its commitment to increase patient access to anti-obesity medications, Novo Nordisk, according to a company representative on Thursday, collaborates with all payers. For further information on the insurance spending cap, they referred CNBC to Cigna.
The endeavor was dubbed by the business the “first financial guarantee” for GLP-1 coverage in the healthcare sector. These medications mimic one or more gut-produced hormones that suppress hunger and control blood sugar in order to treat diabetes and weight loss.